Approval history
The FDA approved Wegovy on June 4, 2021, for adults with obesity, or with overweight and at least one weight-related condition, used together with a reduced-calorie diet and more physical activity. On December 23, 2022, the weight indication was extended to children aged 12 and older with obesity.
Wegovy later gained other uses. On March 8, 2024, the FDA approved it to lower the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and obesity or overweight. On August 15, 2025, it received accelerated approval for noncirrhotic MASH (a fatty liver disease) with moderate to advanced liver fibrosis in adults.
Two new forms followed. A daily tablet, the Wegovy pill, was approved on December 22, 2025. A higher weekly injection dose of 7.2 mg, sold as Wegovy HD, was approved on March 19, 2026.
Medical uses and evidence
Wegovy contains semaglutide, a GLP-1 receptor agonist. The weight approval rests on the STEP trials. In STEP 1, people on Wegovy lost 14.9% of their body weight on average after 68 weeks, compared with 2.4% on placebo.
The heart indication rests on the SELECT trial in people without diabetes. In SELECT, a heart attack, stroke or cardiovascular death occurred in 6.5% of people on semaglutide and 8.0% of people on placebo over a mean follow-up of about 40 months (hazard ratio 0.80).
Forms and doses
Wegovy injection comes in single-dose pens with doses from 0.25 mg to 2.4 mg, plus the 7.2 mg Wegovy HD pen and a multi-dose pen. The label raises the dose step by step over several months, a process called titration. Wegovy HD is not a starting dose: the label reserves it for people who already use the 2.4 mg dose.
Wegovy tablets come in 1.5 mg, 4 mg, 9 mg and 25 mg strengths and are taken once a day.
Side effects and availability
The most common side effects of Wegovy are stomach and gut effects such as nausea, diarrhea, vomiting and constipation. Like other GLP-1 medicines, the label carries a boxed warning about thyroid C-cell tumors seen in rodents.
Wegovy is a prescription medicine. It is sold as a brand-name product, while pharmacies may also prepare compounded semaglutide, which is not an FDA-approved product. Our page on compounded vs. brand-name GLP-1s compares the options.
Timeline
- June 4, 2021FDA approves Wegovy 2.4 mg for chronic weight management in adults.
- December 23, 2022Weight indication extended to ages 12 and older.
- March 8, 2024Cardiovascular risk reduction approved, based on SELECT.
- August 15, 2025Accelerated approval for MASH with moderate to advanced fibrosis.
- December 22, 2025Wegovy tablets (oral semaglutide 25 mg) approved.
- March 19, 2026Wegovy HD 7.2 mg injection approved.
Compare brand and compounded semaglutide
See also
References
- Wegovy (semaglutide) injection and tablets, prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
- Wegovy approved in the US for the treatment of MASH, Novo Nordisk Form 6-K, August 15, 2025. sec.gov
- Wilding et al., NEJM 2021;384:989-1002 (STEP 1). pubmed.ncbi.nlm.nih.gov
- Lincoff et al., NEJM 2023;389:2221-2232 (SELECT). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.